Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Amazon Explores AI Content Marketplace With Media Publishers 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
NEW HAVEN, Conn., March 13, 2018 -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, announced today that it has cancelled its presentation at the Cowen & Company 38th Annual Health Care Conference scheduled for Wednesday, March 14, 2018 in Boston, due to the severe weather that has been forecast for the region. Company President and CEO Dan Wechsler had been scheduled to speak.
Melinta will post the presentation material to the Events & Presentations section of its Investors webpage at http://ir.melinta.com/events.
About Melinta Therapeutics
Melinta Therapeutics, Inc. is the largest pure-play antibiotics company, dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development and commercialization of novel antibiotics that provide new and better therapeutic solutions. Its four marketed products include Baxdela™ (delafloxacin), Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection. It also has an extensive pipeline of preclinical and clinical-stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this portfolio provides Melinta with the unique ability to provide providers and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections. Visit www.melinta.com for more information.
For More Information:
Media Inquiries:
Amra Maynard
(917) 302-2702
[email protected]
Investor Inquiries:
Lisa DeFrancesco
(847) 681-3217
[email protected]
Raj Mistry
(312) 801-2051
[email protected]
